Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 171 - 180 of 243
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: Vel's College of Pharmacy
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Phosphodiesterase 3, 5, 9, PDE3A
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Target Identification
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Vaginal Gel, Vaginal Ring
Developer: Ottawa Hospital Research Institute (OHRI)
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Oral
Developer: HRA Pharma, Gynuity Health Projects, PATH
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Oral
Developer: Stanford University
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Helm Pharmaceuticals, Fresenius Kabi
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: Amphora® Gel, lactic acid, citric acid, and potassium bitartrate
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Evofem Biosciences, Inc.
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Tianjin Condombao Medical Polyurethane Tech. Co. Ltd
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), FHI 360
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: Vel's College of Pharmacy
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 11 - 20 of 70
Alternative Name: ATPase Plasma Membrane Calcium Transporting 4, PMCA4, Plasma Membrane Calcium-Transporting ATPase 4, PMCA4b, PMCA4x, Matrix-Remodeling-Associated Protein 1, Sarcolemmal Calcium Pump, EC 7.2.2.10, EC 3.6.3.8, EC 3.6.3
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Norfolk State University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: University of Cincinnati
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Subdermal
Developer: Murdoch University
Development Stage: Prototype Development
Alternative Name: Bromodomain Testis Associated, Cancer/Testis Antigen 9, Bromodomain Testis-Specific Protein, Bromodomain, Testis-Specific, RING3-Like Protein, CT9, SPGF21, BRD6
Target
User: Male
Hormonal: No
Delivery Method: Injectable, Oral
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Bar-Ilan University
Development Stage: Compound ID/Selection
Alternative Name: Calcium Binding Tyrosine Phosphorylation Regulated, Cancer/Testis Antigen 88, Calcium-Binding Tyrosine Phosphorylation-Regulated Protein, Testis-Specific Calcium-Binding Protein CBP86, Calcium-Binding Protein 86, Fibrousheathin II, Fibrousheathin-2, CBP86, FSP-2, CT88, FSP2
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Calrecticulin 3, Calsperin, Cancer/Testis Antigen 93, Calreticulin-2, CRT2, Testis Secretory Sperm-Binding Protein Li 226n, CMH19, CT93
Target
User: Male
Hormonal: No
Development Stage: Target Validation
Target
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital, Emergency
Developer: Hydra Biosciences, University of Minnesota, University of California at Berkeley, Harvard University, Dare BioScience Inc.
Development Stage: Lead Optimization
Alternative Name: Cyclin-dependent kinases (CDKs)
Target
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota, Moffitt Cancer Center at University of South Florida
Development Stage: Target Identification

Pages

Displaying 31 - 40 of 121
Alternative Name: Estetrol (E4) + Drospirenone (DRSP) Combined Pill
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Mithra
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Hera Health Solutions
Development Stage: Pre-clinical
Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs
User: Female
Hormonal: Yes
Developer: Evestra, Inc.
Development Stage: Pre-clinical
Alternative Name: Etonogestrel (ENG) + Ethinyl Estradiol (EE) Vaginal Ring; EVE112
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Evestra, Inc., Gedeon Richter Plc.
Development Stage: Phase III
Alternative Name: Antiestrogen ICI 182780; Fulvestrant
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: Femasys Inc
Development Stage: Phase I
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: University of Washington, Focused Scientific
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: University of Mumbai
Development Stage: Pre-clinical
Alternative Name: Single Rod GES Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Phase III
Alternative Name: GES VR
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal Ring
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Pre-clinical

Pages

Displaying 31 - 40 of 52
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Innova Quality S.A.S
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Allergan
Development Stage: Regulatory
Alternative Name: Woman's Condom (WC)
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Shanghai Dahua Medical Apparatus Co., Ltd, PATH
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Helm Pharmaceuticals, Fresenius Kabi
Development Stage: Marketed
Alternative Name: Amphora® Gel, lactic acid, citric acid, and potassium bitartrate
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Evofem Biosciences, Inc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Tianjin Condombao Medical Polyurethane Tech. Co. Ltd
Development Stage: SRA/WHO PQ Approved
Alternative Name: Pregna PPIUD T Cu 380A
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: SRA/WHO PQ Approved
Alternative Name: Progestin Vaginal Ring (PVR)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Population Council, Grunenthal
Development Stage: Marketed
Alternative Name: VA w.o.w.
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited, IXu LLC
Development Stage: SRA/WHO PQ Approved

Pages

CSV